In today's competitive economic climate, more and more biopharmaceutical organizations are looking to emerging markets to reduce their clinical study timelines, and hence overall development costs, through more effective patient enrollment.
San Francisco, CA (PRWEB) March 4, 2011
ClinStar, LLC, an established CRO providing clinical research services in Russia and Eastern Europe to the pharmaceutical, biotechnology and medical device industry, announced today that President and CEO David Passov will speak at Arena International's Outsourcing in Clinical Trials East Coast, March 9-10, at The Palace at Somerset Park in Somerset, NJ.
In today's competitive economic climate, more and more biopharmaceutical organizations are looking to emerging markets to reduce their clinical study timelines, and hence overall development costs, through more effective patient enrollment. During his presentation scheduled for Wednesday, March 9 at 1:30 p.m., Mr. Passov will address the definitions and benefits of emerging markets in clinical research with particular emphasis on Russia.
The Outsourcing in Clinical Trials East Coast conference, now in its third year, offers approximately 25 sessions aimed at helping pharmaceutical and biotechnology sponsors optimize partner selection and alliance management strategies in order to maximize their return on outsourcing investment.
About ClinStar, LLC
ClinStar is one of the most prominent CROs in the emerging markets of Eastern Europe and the Baltics, with more than 10 years of expertise in Phase I-IV clinical studies in multiple therapeutic areas. Headquartered in San Francisco, California, ClinStar manages studies from its offices in Russia, Ukraine and Belarus, with total staff of over 300 people. Its portfolio contains over 130 clinical trials conducted for US and European pharmaceutical and biotechnology companies. More information is available at http://www.clinstar.com.